Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14, FiscalAI reports.
Elicio Therapeutics Stock Performance
NASDAQ:ELTX traded up $0.11 during mid-day trading on Friday, reaching $1.51. 756,123 shares of the company’s stock were exchanged, compared to its average volume of 285,067. Elicio Therapeutics has a one year low of $1.25 and a one year high of $16.00. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.77 and a current ratio of 2.77. The business’s fifty day simple moving average is $1.91 and its two-hundred day simple moving average is $6.58. The firm has a market capitalization of $40.91 million, a PE ratio of -0.81 and a beta of 1.64.
Wall Street Analyst Weigh In
ELTX has been the subject of a number of research reports. HC Wainwright restated a “buy” rating on shares of Elicio Therapeutics in a research note on Tuesday, August 18th. B. Riley Financial cut their price objective on shares of Elicio Therapeutics to $8.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Tuesday, October 27th. Finally, Wall Street Zen upgraded Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.
Check Out Our Latest Report on ELTX
About Elicio Therapeutics
Elicio Therapeutics, Inc (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated.
Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.
Featured Stories
- Five stocks we like better than Elicio Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
